Phase 2 Sleep Disorders Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with opioid use disorder (OUD) of at least moderate severity, based on current diagnostic guidelines
- You are currently receiving outpatient treatment for OUD using buprenorphine, either as a dissolvable film or tablet (between 8mg and 24mg) or as a monthly injectable form
- You have been on your current buprenorphine dose for at least 4 weeks and there are no plans to change your dose in the next 3 months
- A urine test at screening shows buprenorphine is present at appropriate levels, as confirmed by a study doctor
- A urine test at screening shows no other non-prescribed substances (marijuana/cannabis is allowed), and a breath or saliva alcohol test is negative
- You screen positive for long-term sleep problems (chronic insomnia) based on a specific sleep questionnaire used in the study
- Your insomnia symptom score is 13 or higher on a standard rating scale, both at screening and at the start of the study
- You do not have any significant medical or mental health conditions that a study doctor believes would make participation unsafe
- You can understand the study procedures and are able to sign a consent form written in English
- You have access to a computer or smartphone with internet or cell service to complete online surveys and monitoring
Who may not be able to join:
- You have been diagnosed with a sleep-related breathing disorder, narcolepsy, sleepwalking, or sleep paralysis
- You screen positive for sleep apnea based on a questionnaire or a home sleep test showing certain levels of breathing interruptions or drops in blood oxygen during sleep (confirm with trial site)
- You are currently receiving any treatment for insomnia, whether that is therapy (such as talk therapy for sleep) or medication
- You are currently taking any prescribed or over-the-counter medication or supplement to help with sleep (such as zolpidem/Ambien), or you are unable to stop taking such a product
- You are currently taking benzodiazepines (such as Valium or Xanax), other opioids besides buprenorphine, antipsychotics, or other medications that affect the brain and nervous system that could increase safety risks
- You have a current diagnosis of alcohol or drug use disorder (other than nicotine) and have used non-prescribed substances in the past 3 months
- You use cannabis/marijuana more than 3 days per week
- You have an uncontrolled serious mental health condition such as Bipolar I Disorder, ADHD, Schizophrenia, schizoaffective disorder, major depression with psychotic features, or a neurological disorder
- You have an uncontrolled serious condition affecting the nervous system, heart, or lungs, such as a seizure disorder, recent heart attack, stroke, or a recent hospital stay for a lung condition
- Your heart test (ECG) at the start of the study shows a significant abnormality, including a specific heart rhythm measurement (QTc) above 450ms
- You currently have significant thoughts of harming yourself or others, or you have attempted suicide in the past 6 months
- Your blood test results show that your liver or kidney function values are significantly above the normal range (confirm with trial site for specific numbers)
- You are pregnant, breastfeeding, or — if there is a possibility you could become pregnant — you are unwilling to use an acceptable form of birth control during the study
- You are currently taking certain prescription or over-the-counter medications or supplements that are known to strongly interact with how the body processes some drugs — this includes certain antibiotics, antifungals, HIV medications, and herbal supplements such as St. John's Wort (confirm with trial site for the full list)
- You are currently taking a sleep medication called lemborexant, or you have had a bad reaction to lemborexant or similar medications in the past
- You are currently incarcerated or facing upcoming incarceration
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Caitlin E Martin, MD, Virginia Commonwealth University Institute for Drug and Alcohol Studies
Phone: 804-827-3784
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Insomnia; Impulsivity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.